Generate Biomedicines (NASDAQ:GENB) Trading 6.6% Higher – Should You Buy?

Generate Biomedicines Inc (NASDAQ:GENB) shot up 6.6% during trading on Monday . The stock traded as high as $17.66 and last traded at $17.5550. 184,085 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 670,269 shares. The stock had previously closed at $16.47.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GENB shares. Piper Sandler started coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target for the company. Wall Street Zen downgraded shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Guggenheim started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $30.00 target price for the company. Cantor Fitzgerald initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating on the stock. Finally, Zacks Research raised Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Generate Biomedicines presently has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Stock Performance

The company has a 50 day moving average of $13.76.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.